Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

BACKGROUND: The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking. Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohlmann, Carsten-Henning, Jäschke, Michelle, Jaehnig, Peter, Krege, Susane, Gschwend, Jürgen, Rexer, Heidrun, Stöckle, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628432/
https://www.ncbi.nlm.nih.gov/pubmed/28978327
http://dx.doi.org/10.1186/s13063-017-2195-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628432/
https://www.ncbi.nlm.nih.gov/pubmed/28978327
http://dx.doi.org/10.1186/s13063-017-2195-x

Ejemplares similares